This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia. Tyrosine kinase inhibitors (TKI) are associated with numerous potential side effects, including a decrease in bone marrow activity (myelosuppression), nausea, diarrhea, fatigue, and soft-tissue swelling (edema), especially in the face and lower legs, which are the primary reasons for patients to discontinue TKI medication. Using a mobile text messaging (TXT) intervention that emphasizes the importance of TKI compliance may improve TKI adherence in patients with chronic myeloid leukemia.
PHASE 1: Patients diagnosed with chronic myeloid leukemia PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year PHASE 1: Able to read and understand English PHASE 1: Able to provide informed consent PHASE 1: Have a mobile phone with TXT capability PHASE 1: Know how to use TXT PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase inhibitors with anticipation of at least 6 month duration of use PHASE 2: Able to read and understand English PHASE 2: Able to provide informed consent PHASE 2: Have a mobile device with TXT capability PHASE 2: Willing to use a wireless pill bottle during study for 6 months PHASE 2: Know or willing to learn how to use TXT
Exclusion Criteria:
• Cognitive impaired document in the electronic medical record (EMR)
